{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:51:30Z","timestamp":1769907090837,"version":"3.49.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2024,5,9]],"date-time":"2024-05-09T00:00:00Z","timestamp":1715212800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,5,9]],"date-time":"2024-05-09T00:00:00Z","timestamp":1715212800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1007\/s10147-024-02546-8","type":"journal-article","created":{"date-parts":[[2024,5,9]],"date-time":"2024-05-09T07:02:25Z","timestamp":1715238145000},"page":"1115-1121","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["The efficacy and safety of anamorelin among patients with diabetes"],"prefix":"10.1007","volume":"29","author":[{"given":"Kenju","family":"Ando","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4047-2929","authenticated-orcid":false,"given":"Tateaki","family":"Naito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Hamauchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keita","family":"Miura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuichiro","family":"Nishibori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayumi","family":"Tonsho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suguru","family":"Matsuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meiko","family":"Morita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Motoki","family":"Sekikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kosei","family":"Doshita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroaki","family":"Kodama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michitoshi","family":"Yabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noboru","family":"Morikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuko","family":"Iida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuaki","family":"Mamesaya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haruki","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ko","family":"Ryo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazushige","family":"Wakuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Ono","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirotsugu","family":"Kenmotsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haruyasu","family":"Murakami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kentaro","family":"Yamazaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiaki","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,5,9]]},"reference":[{"key":"2546_CR1","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/S1470-2045(10)70218-7","volume":"12","author":"K Fearon","year":"2011","unstructured":"Fearon K, Strasser F, Anker SD et al (2011) Definition and classification of cancer cachexia: an international consensus. Lancet Oncol 12:489\u2013495","journal-title":"Lancet Oncol"},{"key":"2546_CR2","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/S1470-2045(15)00558-6","volume":"17","author":"JS Temel","year":"2016","unstructured":"Temel JS, Abernethy AP, Currow DC et al (2016) Anamorelin in patients with non-small-cell lung cancer and cachexia (ROMANA 1 and ROMANA 2): results from two randomised, double-blind, phase 3 trials. Lancet Oncol 17:519\u2013531","journal-title":"Lancet Oncol"},{"key":"2546_CR3","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1002\/cncr.31128","volume":"124","author":"N Katakami","year":"2018","unstructured":"Katakami N, Uchino J, Yokoyama T et al (2018) Anamorelin (ONO-7643) for the treatment of patients with non-small cell lung cancer and cachexia: results from a randomized, double-blind, placebo-controlled, multicenter study of Japanese patients (ONO-7643-04). Cancer 124:606\u2013616","journal-title":"Cancer"},{"key":"2546_CR4","doi-asserted-by":"publisher","first-page":"4294","DOI":"10.1002\/cncr.32406","volume":"125","author":"S Hamauchi","year":"2019","unstructured":"Hamauchi S, Furuse J, Takano T et al (2019) A multicenter, open-label, single-arm study of anamorelin (ONO-7643) in advanced gastrointestinal cancer patients with cancer cachexia. Cancer 125:4294\u20134302","journal-title":"Cancer"},{"key":"2546_CR5","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/s00520-023-07576-y","volume":"31","author":"N Iwai","year":"2023","unstructured":"Iwai N, Sakai H, Oka K et al (2023) Predictors of response to anamorelin in gastrointestinal cancer patients with cachexia: a retrospective study. Support Care Cancer 31:115","journal-title":"Support Care Cancer"},{"key":"2546_CR6","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.2169\/internalmedicine.0730-22","volume":"62","author":"T Takeda","year":"2023","unstructured":"Takeda T, Sasaki T, Okamoto T et al (2023) Impact of the extent of weight loss before administration on the efficacy of anamorelin in advanced pancreatic cancer patients with cachexia. Intern Med 62:1887\u20131893","journal-title":"Intern Med"},{"issue":"Suppl 2","key":"2546_CR7","doi-asserted-by":"publisher","first-page":"ii18","DOI":"10.1093\/annonc\/mdx815","volume":"29","author":"R Dev","year":"2018","unstructured":"Dev R, Bruera E, Dalal S (2018) Insulin resistance and body composition in cancer patients. Ann Oncol 29(Suppl 2):ii18\u2013ii26","journal-title":"Ann Oncol"},{"key":"2546_CR8","doi-asserted-by":"publisher","first-page":"g7607","DOI":"10.1136\/bmj.g7607","volume":"350","author":"KK Tsilidis","year":"2015","unstructured":"Tsilidis KK, Kasimis JC, Lopez DS et al (2015) Type 2 diabetes and cancer: umbrella review of meta-analyses of observational studies. BMJ 350:g7607","journal-title":"BMJ"},{"key":"2546_CR9","first-page":"e124952","volume":"4","author":"Y Hirata","year":"2019","unstructured":"Hirata Y, Nomura K, Senga Y et al (2019) Hyperglycemia induces skeletal muscle atrophy via a WWP1\/KLF15 axis. Insight 4:e124952","journal-title":"Insight"},{"key":"2546_CR10","doi-asserted-by":"publisher","first-page":"101729","DOI":"10.1016\/j.molmet.2023.101729","volume":"73","author":"A Chovsepian","year":"2023","unstructured":"Chovsepian A, Prokopchuk O, Petrova G et al (2023) Diabetes increases mortality in patients with pancreatic and colorectal cancer by promoting cachexia and its associated inflammatory status. Mol Metab 73:101729","journal-title":"Mol Metab"},{"issue":"Suppl 1","key":"2546_CR11","doi-asserted-by":"publisher","first-page":"S19","DOI":"10.2337\/dc23-S002","volume":"46","author":"NA ElSayed","year":"2023","unstructured":"ElSayed NA, Aleppo G, Aroda VR et al (2023) 2. Classification and diagnosis of diabetes: standards of care in diabetes-2023. Diabetes Care 46(Suppl 1):S19\u2013S40","journal-title":"Diabetes Care"},{"issue":"3","key":"2546_CR12","doi-asserted-by":"publisher","first-page":"2918","DOI":"10.1002\/cam4.5206","volume":"12","author":"H Takayama","year":"2023","unstructured":"Takayama H, Takiguchi T, Komura N et al (2023) Efficacy and safety of anamorelin in patients with cancer cachexia: Post-hoc subgroup analyses of a placebo-controlled study. Cancer Med 12(3):2918\u20132928","journal-title":"Cancer Med"},{"key":"2546_CR13","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.ghir.2008.12.003","volume":"19","author":"JM Garcia","year":"2009","unstructured":"Garcia JM, Polvino WJ (2009) Pharmacodynamic hormonal effects of anamorelin, a novel oral ghrelin mimetic and growth hormone secretagogue in healthy volunteers. Growth Horm IGF Res 19:267\u2013273","journal-title":"Growth Horm IGF Res"},{"key":"2546_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ghir.2023.101536","volume":"69\u201370","author":"M Miyazaki","year":"2023","unstructured":"Miyazaki M, Sawada A, Sawamura D et al (2023) Decreased insulin-like growth factor-1 expression in response to mechanical loading is associated with skeletal muscle anabolic resistance in cancer cachexia. Growth Horm IGF Res 69\u201370:101536","journal-title":"Growth Horm IGF Res"},{"key":"2546_CR15","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.ecl.2012.04.017","volume":"41","author":"DR Clemmons","year":"2012","unstructured":"Clemmons DR (2012) Metabolic actions of insulin-like growth factor-I in normal physiology and diabetes. Endocrinol Metab Clin North Am 41:425\u2013443","journal-title":"Endocrinol Metab Clin North Am"},{"key":"2546_CR16","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.ghir.2016.03.002","volume":"29","author":"K Suda","year":"2016","unstructured":"Suda K, Matsumoto R, Fukuoka H et al (2016) The influence of type 2 diabetes on serum GH and IGF-I levels in hospitalized Japanese patients. Growth Horm IGF Res 29:4\u201310","journal-title":"Growth Horm IGF Res"},{"key":"2546_CR17","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s13539-011-0051-5","volume":"3","author":"MA Honors","year":"2012","unstructured":"Honors MA, Kinzig KP (2012) The role of insulin resistance in the development of muscle wasting during cancer cachexia. J Cachexia Sarcopenia Muscle 3:5\u201311","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"2546_CR18","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1002\/jcsm.13073","volume":"14","author":"A Martin","year":"2023","unstructured":"Martin A, Gallot YS, Freyssenet D (2023) Molecular mechanisms of cancer cachexia-related loss of skeletal muscle mass: data analysis from preclinical and clinical studies. J Cachexia Sarcopenia Muscle 14:1150\u20131167","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"2546_CR19","doi-asserted-by":"publisher","first-page":"R21","DOI":"10.1530\/EJE-14-0183","volume":"171","author":"KM Heppner","year":"2014","unstructured":"Heppner KM, Tong J (2014) Mechanisms in endocrinology: regulation of glucose metabolism by the ghrelin system: multiple players and multiple actions. Eur J Endocrinol 171:R21\u2013R32","journal-title":"Eur J Endocrinol"},{"issue":"12","key":"2546_CR20","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1159\/000533539","volume":"101","author":"H Ohta","year":"2023","unstructured":"Ohta H, Horii T, Yasu T (2023) Adverse metabolic effects on glucose in patients receiving anamorelin using a japanese claims database. Oncology 101(12):782\u2013785","journal-title":"Oncology"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-024-02546-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-024-02546-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-024-02546-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,25]],"date-time":"2024-07-25T05:28:49Z","timestamp":1721885329000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-024-02546-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,9]]},"references-count":20,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["2546"],"URL":"https:\/\/doi.org\/10.1007\/s10147-024-02546-8","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,9]]},"assertion":[{"value":"11 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Tateaki Naito received grants from Otsuka Pharmaceutical K. K. and Japan\u2019s Agency for Medical Research and Development (AMED), and personal fees from Ono Pharmaceutical Co., Ltd., and Helsinn Healthcare SA outside of the submitted work. Keita Miura received personal fees from AstraZeneca, Chugai Pharmaceutical, and Taiho Pharmaceutical outside of the submitted work. Motoki Sekikawa received personal fees from Chugai Pharmaceutical Co. Ltd. and Takeda Pharmaceutical outside of the submitted work. Hiroaki Kodama received personal fees from Chugai Pharmaceutical Co., Ltd., and Novartis Pharma K. K. outside of the submitted work. Nobuaki Mamesaya received grants and personal fees from Boehringer Ingelheim, and personal fees from Chugai Pharmaceutical Co., Ltd., Taiho Pharmaceuticals, MSD K. K., AstraZeneca K. K., and Ono Pharmaceutical Co., Ltd. outside of the submitted work. Haruki Kobayashi received personal fees from Eli Lilly K. K., Novartis Pharma K. K., Taiho Pharmaceutical., AstraZeneca K. K., Chugai Pharmaceutical Co., Ltd., Ono Pharmaceutical Co., Ltd., Bristol-Myers Squibb Company, and Daiichi Sankyo Co. outside of the submitted work. Ko Ryo received grants and personal fees from MSD K. K. and AstraZeneca K.K., and personal fees from Taiho Pharmaceuticals, Chugai Pharmaceutical Co., Ltd., Eli Lilly K. K., Ono Pharmaceutical, Daiichi Sankyo, and Takeda, outside of the submitted work. Kazushige Wakuda received grants and personal fees from Chugai Pharmaceutical Co., Ltd., AstraZeneca K.K., MSD K. K., Daiichi Sankyo Co., Ltd., and grants from Novartis Pharma K. K.; AbbVie, AMGEN, and Dizal Pharma, and personal fees from Taiho Pharmaceutical, Boehringer Ingelheim, Eli Lilly K. K., Ono Pharmaceutical, Janssen Pharmaceutical K. K., Takeda Pharmaceutical, and Nihon Kayaku outside of the submitted work. Akira Ono received personal fees from AstraZeneca K. K., Chugai Pharmaceutical Co., Ltd., Ono Pharmaceutical Co., Ltd., and Indica Laboratories outside of the submitted work. Hirotsugu Kenmotsu received personal fees from AMGEN, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Chugai Pharmaceutical Co., Daiichi-Sankyo Co., Ltd., Kyowa Hakko Kirin Co., Ltd., Taiho Pharmaceuticals, Takeda Pharmaceutical Co., Ltd., Merck Biopharma Co., Ltd., MSD K. K., and Pfizer, and grants and personal fees from AstraZeneca K. K., Novartis Pharma K. K., Ono Pharmaceutical Co., Ltd., and Eli Lily K. K., and grants from Loxo Oncology, outside of the submitted work. Haruyasu Murakami received grants and personal fees from AstraZeneca K. K., Takeda Pharmaceutical Co., Ltd., Daiichi-Sankyo Co., Chugai Pharmaceutical Co. Ltd., and Taiho Pharmaceutical, grants from AbbVie and IQvia, Bayer, and personal fees from Amgen, Ono Pharmaceutical Co., Ltd., Bristol-Myers Squibb Japan, MSD K. K., Pfizer Inc., Novartis Pharma K. K., Eli Lilly Japan K. K., Eisai, and Nihon Kayaku, outside of the submitted work. Toshiaki Takahashi received grants and personal fees from AstraZeneca K.K., Chugai Pharmaceutical Co., Ltd., Eli Lilly Japan K. K., MSD, Pfizer Japan Inc., and Amgen Inc., personal fees from Ono Pharmaceutical Co., Ltd., BMS Japan, Takeda Pharmaceuticals Co., and Novartis You, and grants from Merck Biopharma Co., Ltd., Janssen Pharmaceutical K. K., and AnHeart Therapeutics Inc. outside of the submitted work. The remaining authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}}]}}